Cargando…

Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia

The indoleamine 2,3-dioxygenase (IDO) enzyme is the first rate-limiting enzyme of the tryptophan degradation pathway in which dysfunction of neuroactive metabolites has been implicated in the pathophysiology of schizophrenia. Inflammatory molecules such as pro-inflammatory cytokines could enhance th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Shi, Han, Yang, Ge, Yang, Yongfeng, Li, Wenqiang, Song, Meng, Shao, Minglong, Su, Xi, Lv, Luxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606005/
https://www.ncbi.nlm.nih.gov/pubmed/34802039
http://dx.doi.org/10.1038/s41398-021-01688-x
_version_ 1784602265256984576
author Zhang, Yan
Shi, Han
Yang, Ge
Yang, Yongfeng
Li, Wenqiang
Song, Meng
Shao, Minglong
Su, Xi
Lv, Luxian
author_facet Zhang, Yan
Shi, Han
Yang, Ge
Yang, Yongfeng
Li, Wenqiang
Song, Meng
Shao, Minglong
Su, Xi
Lv, Luxian
author_sort Zhang, Yan
collection PubMed
description The indoleamine 2,3-dioxygenase (IDO) enzyme is the first rate-limiting enzyme of the tryptophan degradation pathway in which dysfunction of neuroactive metabolites has been implicated in the pathophysiology of schizophrenia. Inflammatory molecules such as pro-inflammatory cytokines could enhance the activity of IDO. There are few studies on the expression of IDO levels and its correlation with levels of inflammatory cytokines in first-episode drug-naive patients with schizophrenia. One hundred inpatients (female = 33, male = 67) with first-episode drug-naive schizophrenia entered a 6-week, double-blind, randomized, placebo-controlled clinical trial. All individuals were assigned celecoxib or placebo combined with risperidone. Serum levels of IDO and six inflammatory cytokines (IL-1β, IL-6, TNF-α IL-17, IL-4, and INF-γ) were measured. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of psychotic symptoms. Compared to healthy subjects, patients had significantly elevated levels of IDO and six cytokines at baseline. Over the 6-week treatment period, the decrease in the levels of IDO and TNF-α and the improvement in the PANSS total score, positive scores, and negative scores in the celecoxib group were significantly greater than in the placebo group. There was a significantly positive correlation between IDO levels and the PANSS negative scores and between IDO levels and TNF-α and IFN-γ levels in the celecoxib group. These findings showed abnormal expression of IDO levels which correlated with negative symptoms and pro-inflammatory cytokine levels in patients with first-episode drug-naive schizophrenia, suggesting the important role of IDO in the pathological mechanism of schizophrenia. Registration number: ChiCTR2000041403.
format Online
Article
Text
id pubmed-8606005
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86060052021-12-03 Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia Zhang, Yan Shi, Han Yang, Ge Yang, Yongfeng Li, Wenqiang Song, Meng Shao, Minglong Su, Xi Lv, Luxian Transl Psychiatry Article The indoleamine 2,3-dioxygenase (IDO) enzyme is the first rate-limiting enzyme of the tryptophan degradation pathway in which dysfunction of neuroactive metabolites has been implicated in the pathophysiology of schizophrenia. Inflammatory molecules such as pro-inflammatory cytokines could enhance the activity of IDO. There are few studies on the expression of IDO levels and its correlation with levels of inflammatory cytokines in first-episode drug-naive patients with schizophrenia. One hundred inpatients (female = 33, male = 67) with first-episode drug-naive schizophrenia entered a 6-week, double-blind, randomized, placebo-controlled clinical trial. All individuals were assigned celecoxib or placebo combined with risperidone. Serum levels of IDO and six inflammatory cytokines (IL-1β, IL-6, TNF-α IL-17, IL-4, and INF-γ) were measured. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of psychotic symptoms. Compared to healthy subjects, patients had significantly elevated levels of IDO and six cytokines at baseline. Over the 6-week treatment period, the decrease in the levels of IDO and TNF-α and the improvement in the PANSS total score, positive scores, and negative scores in the celecoxib group were significantly greater than in the placebo group. There was a significantly positive correlation between IDO levels and the PANSS negative scores and between IDO levels and TNF-α and IFN-γ levels in the celecoxib group. These findings showed abnormal expression of IDO levels which correlated with negative symptoms and pro-inflammatory cytokine levels in patients with first-episode drug-naive schizophrenia, suggesting the important role of IDO in the pathological mechanism of schizophrenia. Registration number: ChiCTR2000041403. Nature Publishing Group UK 2021-11-20 /pmc/articles/PMC8606005/ /pubmed/34802039 http://dx.doi.org/10.1038/s41398-021-01688-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhang, Yan
Shi, Han
Yang, Ge
Yang, Yongfeng
Li, Wenqiang
Song, Meng
Shao, Minglong
Su, Xi
Lv, Luxian
Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia
title Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia
title_full Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia
title_fullStr Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia
title_full_unstemmed Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia
title_short Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia
title_sort associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606005/
https://www.ncbi.nlm.nih.gov/pubmed/34802039
http://dx.doi.org/10.1038/s41398-021-01688-x
work_keys_str_mv AT zhangyan associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT shihan associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT yangge associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT yangyongfeng associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT liwenqiang associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT songmeng associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT shaominglong associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT suxi associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia
AT lvluxian associationsbetweenexpressionofindoleamine23dioxygenaseenzymeandinflammatorycytokinesinpatientswithfirstepisodedrugnaiveschizophrenia